Taisho Pharmaceutical will bring its experience and expertise in the research and development of therapeutic products to the collaboration.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Appoints Dr Rafiq Hasan as CEO
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Dr. Raman has succeeded Victoria Richon
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Subscribe To Our Newsletter & Stay Updated
